March 29, 2016 — IBA (Ion Beam Applications S.A.) announced the sale of IBA Molecular (IBAM) in which IBA had a 40 percent stake, to funds advised by CapVest Partners LP (“CapVest”), has closed successfully. With this transaction, IBA has fully exited its joint venture with SK Capital Partners and retains no interests in IBA Molecular.
IBAM produces radiopharmaceuticals for radiation therapy and radiotracers used for molecular imaging.
The closing of this transaction is completed by a payment in cash to IBA of circa EUR 62 million.
IBA is now focused on the field of proton therapy. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.
CapVest is an established European mid-market private equity firm focused on acquiring market-leading companies supplying essential products and services. The firm places an emphasis on driving business growth through active management and has demonstrated consistent success in creating long-term value.
For more information: www.ibamolecular.eu
July 30, 2024 
